In vitro and in vivo effects of metformin on human adipose tissue adiponectin

Obesity Facts

Volumn 4, Issue 1, 2011, Pages 27-33

  Zulian, Alessandra ^a   Cancello, Raffaella ^a   Girola, Andrea ^a   Gilardini, Luisa ^a   Alberti, Luisella ^a   Croci, Marina ^a   Micheletto, Giancarlo ^b   Danelli, Piergiorgio ^c   Invitti, Cecilia ^a  

^a ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Adiponectin; Adipose tissue; Insulin resistance; Metformin; Obesity

Indexed keywords

ADIPONECTIN; CD68 ANTIGEN; METFORMIN; PLACEBO;

ADIPOCYTE; ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INTRAABDOMINAL FAT; LIFESTYLE; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN SECRETION; SUBCUTANEOUS FAT;

ADIPONECTIN; ADIPOSE TISSUE; ADULT; CELLS, CULTURED; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INTRA-ABDOMINAL FAT; LIFE STYLE; METFORMIN; OBESITY; SUBCUTANEOUS FAT;

EID: 79952384985     PISSN: 16624025     EISSN: 16624033     Source Type: Journal    
DOI: 10.1159/000324582     Document Type: Article

References (36)

1. Hunda RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, Inzucchi SE, Schumann WC, Petersen KF, Landau BR, Shulman GI: Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000;49:2063-2069.
2. Tiikkainen M, Hakkinen AM, Korsheninnikova E, Nyman T, Makimattila S, Yki-Jarvinen H: Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004;53:2169-2176. (Pubitemid 38970772)
3. Zhang T, He J, Xu C, Zu L, Jiang H, Pu S, Guo X, Xu G: Mechanisms of metformin inhibiting lipolytic response to isoproterenol in primary rat adipocytes. J Mol Endocrinol 2009;42:57-66.
4. Galuska D, Nolte LA, Zierath JR, Wallberg-Henriksson H: Effect of metformin on insulin-stimulated glucose transport in isolated skeletal muscle obtained from patients with NIDDM. Diabetologia 1994;37:826-832. (Pubitemid 24247854)
5. Hother-Nielsen O, Schmitz O, Andersen PH, Beck-Nielsen H, Pedersen O: Metformin improves peripheral but not hepatic insulin action in obese patients with type II diabetes. Acta Endocrinol (Copenh) 1989;120:257-265. (Pubitemid 19073610)
6. Mithieux G, Rajas F, Zitoun C: Glucose utilization is suppressed in the gut of insulin-resistant high fat-fed rats and is restored by metformin. Biochem Pharmacol 2006;72:1757-1762.
7. Marchetti P, Del Guerra S, Marselli L, Lupi R, Masini M, Pollera M, Bugliani M, Boggi U, Vistoli F, Mosca F, Del Prato S: Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin. J Clin Endocrinol Metab 2004;89:5535-5541. (Pubitemid 39518437)
8. Wiernsperger NF: 50 years later: is metformin a vascular drug with antidiabetic properties? Br J Diab Vasc Dis 2007;7:204-210. (Pubitemid 350055237)
9. Song J, Ren P, Zhang L, Wang XL, Chen L, Shen YH: Metformin reduces lipid accumulation in macrophages by inhibiting FOXO1-mediated transcription of fatty acid-binding protein 4. Biochem Biophys Res Commun 2010;393:89-94.
10. Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, Bost F: Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther 2010;9:1092-1099.
11. Diamanti-Kandarakis E, Christakou CD, Kandaraki E, Economou FN: Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. Eur J Endocrinol 2010;162:193-212.
12. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, Tsuno NH, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R, Kadowaki T: Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003;423:762-769. (Pubitemid 36735700)
13. Maury E, Brichard SM: Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol 2010;314:1-16.
14. Ohashi K, Parker JL, Ouchi N, Higuchi A, Vita JA, Gokce N, Pedersen AA, Kalthoff C, Tullin S, Sams A, Summer R, Walsh K: Adiponectin promotes macrophage polarization toward an anti-inflammatory phenotype. J Biol Chem 2010;285:6153-6160.
15. Antoniades C, Antonopoulos AS, Tousoulis D, Stefanadis C: Adiponectin: from obesity to cardiovascular disease. Obes Rev 2009;10:269-279.
16. Diez JJ, Iglesias P: The role of the novel adipocytederived hormone adiponectin in human disease. Eur J Endocrinol 2003;148:293-300. (Pubitemid 36410714)
17. Sporrer D, Weber M, Wanninger J, Weigert J, NeumeierM, Stogbauer F, Lieberer E, Bala M, Kopp A, Schaffler A, Buechler C: Adiponectin downregulates CD163 whose cellular and soluble forms are elevated in obesity. Eur J Clin Invest 2009;39:671-679.
18. Zakikhani M, Dowling RJ, Sonenberg N, Pollak MN: The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res (Phila Pa) 2008;1:369-375.
19. Kola B, Boscaro M, Rutter GA, Grossman AB, Korbonits M: Expanding role of AMPK in endocrinology. Trends Endocrinol Metab 2006;17:205-215. (Pubitemid 43974977)
20. Phillips SA, Ciaraldi TP, Oh DK, Savu MK, Henry RR: Adiponectin secretion and response to pioglitazone is depot dependent in cultured human adipose tissue. Am J Physiol Endocrinol Metab 2008; 295:E842-50.
21. Riera-Guardia N, Rothenbacher D: The effect of thiazolidinediones on adiponectin serum level: a meta-analysis. Diabetes Obes Metab 2008;10:367-375. (Pubitemid 351524284)
22. Adamia N, Virsaladze D, Charkviani N, Skhirtladze M, Khutsishvili M: Effect of metformin therapy on plasma adiponectin and leptin levels in obese and insulin resistant postmenopausal females with type 2 diabetes. Georgian Med News 2007;(145):52-55.
23. Mather KJ, Funahashi T, Matsuzawa Y, Edelstein S, Bray GA, Kahn SE, Crandall J, Marcovina S, Goldstein B, Goldberg R, Diabetes Prevention Program: Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program. Diabetes 2008;57:980-986.
24. Jakubowska J, Bohdanowicz-Pawlak A, Milewicz A, Szymczak J, Bednarek-Tupikowska G, Demissie M: Plasma cytokines in obese women with polycystic ovary syndrome, before and after metformin treatment. Gynecol Endocrinol 2008;24:378-384. (Pubitemid 352032225)
25. Sharma PK, Bhansali A, Sialy R, Malhotra S, Pandhi P: Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus. Clin Endocrinol (Oxf) 2006;65:722-728. (Pubitemid 44772351)
26. Phillips SA, Ciaraldi TP, Kong AP, Bandukwala R, Aroda V, Carter L, Baxi S, Mudaliar SR, Henry RR: Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes 2003;52:667-674. (Pubitemid 36323573)
27. Huypens P, Quartier E, Pipeleers D, Van de Casteele M: Metformin reduces adiponectin protein expression and release in 3T3-L1 adipocytes involving activation of AMP activated protein kinase. Eur J Pharmacol 2005;518:90-95. (Pubitemid 41133630)
28. Sinaki M, Kenneth P, Offord P: Physical activity in postmenopausal women: effect on back muscle strength and bone mineral density of the spine. Arch Phys Med Rehabil 1988; 69:277-280.
29. Phillips SA, Kung J, Ciaraldi TP, Choe C, Christiansen L, Mudaliar S, Henry RR: Selective regulation of cellular and secreted multimeric adiponectin by antidiabetic therapies in humans. Am J Physiol Endocrinol Metab 2009;297:E767-73.
30. Schraw T, Wang ZV, Halberg N, Hawkins M, Scherer PE: Plasma adiponectin complexes have distinct biochemical characteristics. Endocrinology 2008;149:2270-2282. (Pubitemid 351574488)
31. Wang ZV, Schraw TD, Kim JY, Khan T, Rajala MW, Follenzi A, Scherer PE: Secretion of the adipocyte- specific secretory protein adiponectin critically depends on thiol-mediated protein retention. Mol Cell Biol 2007;27:3716-3731. (Pubitemid 46726179)
32. Isoda K, Young JL, Zirlik A, MacFarlane LA, Tsuboi N, Gerdes N, Schonbeck U, Libby P: Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells. Arterioscler Thromb Vasc Biol 2006;26:611-617.
33. Haffner S, Temprosa M, Crandall J, Fowler S, Goldberg R, Horton E, Marcovina S, Mather K, Orchard T, Ratner R, Barrett-Connor E, Diabetes Prevention Program Research Group: Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes 2005;54:1566-1572.
34. Dandona P, Aljada A, Ghanim H, Mohanty P, Tripathy C, Hofmeyer D, Chaudhuri A: Increased plasma concentration of macrophage migration inhibitory factor (MIF) and MIF mRNA in mononuclear cells in the obese and the suppressive action of metformin. J Clin Endocrinol Metab 2004;89: 5043-5047. (Pubitemid 39391446)
35. Wolf G: New insights into thiol-mediated regulation of adiponectin secretion. Nutr Rev 2008;66:642-645.
36. Perrini S, Laviola L, Cignarelli A, Melchiorre M, De Stefano F, Caccioppoli C, Natalicchio A, Orlando MR, Garruti G, De Fazio M, Catalano G, Memeo V, Giorgino R, Giorgino F: Fat depotrelated differences in gene expression, adiponectin secretion, and insulin action and signalling in human adipocytes differentiated in vitro from precursor stromal cells. Diabetologia 2008;51:155-164. (Pubitemid 350197987)